#USA #Boston #oncology #cancer therapies #Privo Technologies

Strengthening Cancer Treatment: Privo Technologies' Recent Patent Achievements

In a significant announcement, Privo Technologies, a cutting-edge biopharmaceutical firm focused on localized cancer therapies, has made notable strides in enhancing its intellectual property portfolio. The company recently reported the issuance of several new patents within the United States, Canada, and India. Furthermore, they are in the process of securing patents in other key regions, including Japan, Australia, and Europe. As of mid-October 2026, Privo boasts a robust collection of 13 patents that have either been issued or approved.

These recent developments reveal Privo’s commitment to advancing its proprietary delivery technologies, which include their innovative PRV111 topical patch, PRV211 intraoperative patch, and PRV131 intratumoral injectable programs. Dr. Manijeh Goldberg, CEO, President, and Founder of Privo, highlighted that this intellectual property expansion stands as a testament to the years of dedication, scientific rigor, and investment that the company has contributed towards enhancing its oncology platform.

“Privo's innovation lies in how we formulate and deliver cancer treatment directly to diseased tissue,” stated Dr. Goldberg. This statement encapsulates the essence of Privo's mission to minimize systemic exposure while ensuring that high doses of anticancer therapies reach the targeted areas effectively. Such an approach not only signifies a potential shift in cancer treatment methodologies but also underscores the importance of personalized medicine in today's healthcare landscape.

Building on its existing U.S. patent estate, Privo holds a history of developing rapid-release patch technologies that offer quick and efficient delivery systems essential for intraoperative and topical applications. The company's strategic intellectual property framework integrates patents related to composition, delivery systems, and proprietary manufacturing insights. This multifaceted approach reiterates Privo's commitment to innovation and leadership in the biopharmaceutical space.

To further elaborate, the intellectual property strategy employed by Privo results in sophisticated manufacturing processes, contributing to the consistent quality of its oncology therapies. The company excels at delivering localized therapies that preserve patient quality of life, thereby enhancing treatment outcomes without compromising their wellbeing. As the healthcare industry continues to evolve, Privo’s strategies position them favorably within the biopharmaceutical landscape, paving the way for future partnerships and potential commercialization of their advanced therapies.

Privo Technologies is tirelessly working towards developing localized, minimally invasive treatments for solid tumors, utilizing their proprietary nanoengineered delivery platform to change cancer treatment paradigms profoundly. Given the sickness burden of cancer across the globe, Privo's innovative approach not only addresses urgent patient needs but also resonates with a broader goal to significantly improve cancer care.

To explore more on Privo Technologies and their groundbreaking work on oncology solutions, visit Privo Technologies. For media inquiries, reach out via [email protected]. For business inquiries, contact [email protected].